Please write a review of the post below: including questions to be asked about the post.

Pfizer has acquired Array Biopharma in a strategic positioning move to strengthen its innovative biopharmaceutical business. This merger is expected to accelerate its growth, in the long term. Array's Boulder Colorado research unit will help to complement Pfizer's own research efforts. The total enterprise value of the acquisition of $11.4 Billion.

For Pfizer, this acquisition is beneficial to the strategy on the intellectual property that array owns, and that will now be Pfizer's property. Strengthening and widening the scope of Pfizer will help its profitability and its ability to secure more productive research. Since Pfizer focuses on the Individuals drugs and Array's most profitable market is the discovery and the development of small molecule drugs, bringing them together will help to secure the majority in the market. Pfizer is thinking about the long-term growth and future with the ability to create and maintain the longevity they created during the Covid-19 pandemic. This is an adaptive Strategic move that will help to further their innovation. Pfizer is an innovative company and looking to the future, the need will shift and they are preparing for the change with the acquisition.

The values of Pfizer will not change as they are both in the healthcare space. The changes to the company will come from the angle at which they are innovating. The array is a small molecule, creating a new space for Pfizer to grow in the future. I think that many people within Pfizer will be happy with the purchase. Some of the employees of Array will lose their job and with the acquisition of companies, it never goes as planned but as big as Pfizer is and how many companies they have already acquired in their history I think this will be as smooth as possible. Personally, I am not a fan of the acquisition. I do not believe that pharmaceutical companies should be so big. I believe one of the problems that we have in the US is that companies regulate processes and hurt the consumer. The purchase is too recent to measure the satisfaction of the companies and their feelings